Maitland, Norman J - York University

个人简介

1991 - Professor of Molecular Biology, Director YCR Cancer Research Unit Department of Biology, University of York 1989 - 1991 Senior Lecturer in Molecular Pathology Department of Pathology, University of Bristol 1983 - 1989 New Blood Lecturer in Molecular Pathology Department of Pathology, University of Bristol 1977 - 1983 Cancer Research Campaign Research Fellow Department of Genetics, University of Edinburgh 1976 - 1977 Robertson Research Fellow Cold Spring Harbor Laboratory, New York 1974 - 1977 PhD in Cancer Studies University of Birmingham 1970 - 1974 BSc Biochemistry (First Class Hons) University of Glasgow

研究领域

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

My research in the YCR Cancer Research Unit is now focused on the development and aetiology of human prostate cancer. Our overall approach has been to separate the tumour (and the corresponding normal tissue) into its cellular components, and to study the role played by different cell types. Of particular interest are the roles played by epithelial stem cells and the hormone-sensitive stromal cells within the tumour and normal prostate. We have compiled gene expression profiles for the various cell types using the Affymetrix platform, and have mined this data for genes and signalling pathways which affect cell fate. Much of our research is now concerned with hypothesis testing, based on the identified genes from this study, using complex multicellular models in vitro and developing xenograft models of the tumour. Clearly fate-altering genes also have therapeutic significance, and in a spin out company (Pro-Cure Therapeutics, founded in 2001) an associated research team are developing novel cancer stem cell treatments, based on the output of the YCR Research. There is a close collaboration between the two groups. As part of an International collaboration, coordinated from York, we are also developing novel biotherapies for prostate cancer, based on targeted and stealthed viral vectors, which allow us to either focus gene expression in specific cells within a tumour, or to engineer viruses to replicate only in tumour cells (oncolytics).